These Two Companies’ ADC Products Ride the Wave of Global PD-1 Sales Champions, Why Worry About Future Sales?
We previously mentioned that the current standard treatment for cancer is gradually shifting from PD-1 + chemotherapy to PD-1 + ADC drugs. According to relevant data, the global ADC drug market size has grown from $7.9 billion in 2022 to approximately $20 billion in 2024, showing strong growth momentum. Among them, DS8201 (HER2 ADC), jointly … Read more